NCT06250283View on ClinicalTrials.gov

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NAActive, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

January 30, 2026

Conditions
Low Bone Mass
Interventions
DIETARY_SUPPLEMENT

Resveratrol

Resveratrol (500 mg)

DIETARY_SUPPLEMENT

Placebo

Placebo (500 mg)

Trial Locations (1)

19716

University of Delaware, Newark

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

University of Delaware

OTHER

NCT06250283 - Resveratrol for the Prevention of Bone Loss in Postmenopausal Women | Biotech Hunter | Biotech Hunter